Aussies who are classified as 'moderate to high risk' and are aged between 18 and 64 now qualify for the immunisation.

More than 200,000 Australians who are immunocompromised will gain free access to the shingles vaccine in an expansion of a ...

Topline results were announced from a phase 3 study assessing the immune response following coadministration of Arexvy and Shingrix.

GSK (GSK) reached the main goal in a Phase 3 trial for its RSV shot, Arexvy co--administered with Shingles vaccine Shingrix.

In the study, co-administration of GSK's RSV vaccine Arexvy and shingles shot Shingrix elicited non-inferior immune responses ...

GSK released data from a Phase 3 trial evaluating the co-administration of Arexvy and Shingrix vaccines in adults 50+. The ...

GSK recorded positive topline data in a late stage trial of its respiratory syncytial virus vaccine combined with a shingles vaccine in treating adults 50 years and older.

GSK plc (LSE/NYSE: GSK) today announced positive topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, reactogenicity and safety of AREXVY (Respiratory ...

University of Sydney research has found people over 65 are being prescribed antidepressants as pain treatment based on ...

Symptoms of shingles include pain, itchiness and a rash that looks like a stripe of blisters on the left or right side of the ...